Innovative design of G_i-biased CB1 agonists, LZD503 & LZD505, targets pain relief while minimizing side effects, paving the way for safer non-opioid therapies. PMID:41980782, Cell 2026, @Cell https://www.cell.com/cell/fulltext/S0092-8674(26)00287-4 #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪
